Michael R Eccles
Overview
Explore the profile of Michael R Eccles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1893
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hossain S, Gimenez G, Stockwell P, Weeks R, Almomani S, Jones G, et al.
Cancer Lett
. 2025 Mar;
:217638.
PMID: 40089202
Successful immune checkpoint inhibitor (ICI) therapy occurs in only a fraction of melanoma patients, and yet all patients are susceptible to potentially serious ICI-related side-effects. No current biomarkers robustly predict...
2.
Smith-Diaz C, Kumar A, Das A, Pace P, Chitcholtan K, Magon N, et al.
Free Radic Biol Med
. 2025 Jan;
229:427-440.
PMID: 39793908
Cutaneous melanoma is a highly invasive, heterogeneous and treatment resistant cancer. It's ability to dynamically shift between transcriptional states or phenotypes results in an adaptive cell plasticity that may drive...
3.
Keighley L, Lynch-Sutherland C, McDougall L, Almomani S, Stockwell P, Eccles M, et al.
Placenta
. 2024 Sep;
158:10-13.
PMID: 39312864
Transposable elements (TEs) play a crucial role in placental development and dysfunction. Our study examined TE expression in pre-eclampsia (PE) using RNA-seq datasets. We identified differentially expressed TEs and explored...
4.
Hossain S, Carpenter C, Eccles M
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000359
Immune checkpoint inhibitors (ICIs) demonstrate durable responses, long-term survival benefits, and improved outcomes in cancer patients compared to chemotherapy. However, the majority of cancer patients do not respond to ICIs,...
5.
Li L, Hossain S, Eccles M
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928435
Renal cell carcinoma (RCC) is a significant oncological challenge due to its heterogeneous nature and limited treatment options. The developmental gene family encodes nine highly conserved transcription factors that play...
6.
Banerjee R, Ajithkumar P, Keestra N, Smith J, Gimenez G, Rodger E, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473261
Cutaneous melanoma is rapidly on the rise globally, surpassing the growth rate of other cancers, with metastasis being the primary cause of death in melanoma patients. Consequently, understanding the mechanisms...
7.
Powell R, Moravec J, Jones G, Bhat B, Lin S, Planer J, et al.
Am J Respir Cell Mol Biol
. 2023 Dec;
70(1):81-84.
PMID: 38156802
No abstract available.
8.
Rodger E, Stockwell P, Almomani S, Eccles M, Chatterjee A
STAR Protoc
. 2023 Nov;
4(4):102714.
PMID: 37950864
Aberrant DNA methylation is a universal feature of cancer. Here, we present a protocol for generating high-quality genome-scale DNA methylation sequencing data from a variety of human cancer biospecimens including...
9.
Ravindran Menon D, Hammerlindl H, Gimenez G, Hammerlindl S, Zuegner E, Torrano J, et al.
Drug Resist Updat
. 2023 Aug;
71:100993.
PMID: 37639774
Aims: Drivers of the drug tolerant proliferative persister (DTPP) state have not been well investigated. Histone H3 lysine-4 trimethylation (H3K4me3), an active histone mark, might enable slow cycling drug tolerant...
10.
Li L, Li C, Almomani S, Hossain S, Eccles M
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511191
Renal cell carcinoma (RCC) is the most common form of kidney cancer, consisting of multiple distinct subtypes. RCC has the highest mortality rate amongst the urogenital cancers, with kidney renal...